• 1
    Jones E, Basile A, Skolnick P. Hepatic encephalopathy, GABA-ergic neurotransmission and benzodiazepine receptor ligands. In: GrisoliaS, ed. Cirrhosis, Hepatic Encephalopathy, and Ammonium Toxicity. New York: Plenum, 1990: 121135.
  • 2
    Baraldi M, Zeneroli ML, Ventura E, Penne A, Pinelli G, Ricci P, Santi M. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist. Clin Sci 1984; 67: 167175.
  • 3
    Schafer DF, Fowler JM, Munson PJ, Thakur AK, Waggoner JG, Jones E. Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Lab Clin Med 1983; 102: 870880.
  • 4
    Baraldi M, Zeneroli ZL. Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid. Science 1982; 216: 427429.
  • 5
    Basile AS, Pannell L, Jaouni T, Gammal SH, Fales HM, Jones EA, Skolnick P. Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proc Natl Acad Sci USA 1990; 87: 52635267.
  • 6
    Mullen KD, Martin JV, Mendelson WB, Kaminsky-Russ K, Jones EA. Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy. Metab Brain Dis 1989; 4: 253260.
  • 7
    Basile AS, Gammal SH, Jones EA, Skolnick P. GABAA receptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous benzodiazepine receptor ligand. J Neurochem 1989; 53: 10571063.
  • 8
    Mullen KD, Szauter KM, Kaminsky-Russ K. “Endogenous” benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990; 336: 8183.
  • 9
    Basile AS, Hughes RD, Harrison PM, Murata Y, Pannell L, Jones EA, Williams R, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991; 325: 473478.
  • 10
    Bansky G, Meier PJ, Riederer E, Walser H, Ziegler WH, Schmid M. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989; 97: 744750.
  • 11
    Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 1989; 96: 240243.
  • 12
    Grimm G, Ferenci P, Katzenschlager R, Madl C, Schneeweiss B, Laggner AN, Lenz K, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988; 2: 13921394.
  • 13
    Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788) [Letter]. Lancet 1985; 1: 1324.
  • 14
    Pomier Layrargues G, Giguere JF, Lavoie J, Perney P, Gagnon S, D'Amour M, Wells J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology 1994; 19: 3237.
  • 15
    Bansky G, Meier PJ, Ziegler WH, Walser H, Schmid M, Huber M. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788) [Letter]. Lancet 1985; 1: 13241325.
  • 16
    Samson Y, Bernuau J, Pappata S, Chavoix C, Baron JC, Maziere MA. Cerebral uptake of benzodiazepine measured by positron emission tomography in hepatic encephalopathy [Letter]. N Engl J Med 1987; 316: 414415.
  • 17
    Butterworth RF, Lavoie J, Giguere JF, Pomier-Layrargues G. Affinities and densities of high-affinity [3H]muscimol (GABAA) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 1988; 8: 10841088.
  • 18
    Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, Butterworth RF. Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. Hepatology 1989; 10: 969972.
  • 19
    Janssen U, Walker S, Maier K, von Gaisberg U, Klotz U. Flumazenil disposition and elimination in cirrhosis. Clin Pharmacol Therap 1989; 46: 317323.
  • 20
    Persson A, Pauli S, Swahn CG, Halldin C, Sedvall G. Cerebral uptake of 11C-Ro 15-1788 and its acidic metabolite 11C-Ro 15-3890; PET study in healthy volunteers. Human Psychopharmacol 1989; 4: 215220.
  • 21
    Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE. Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. Ann Neurol 1991; 30: 663672.
  • 22
    Holthoff VA, Koeppe RA, Frey KA, Paradise AH, Kuhl DE. Differentiation of radioligand delivery and binding in the brain. J Cereb Blood Flow Metab 1991; 11: 745752.
  • 23
    Koeppe RA, Holthoff VA, Frey KA, Kilbourn MR, Kuhl DE. Compartmental analysis of [11C] flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991; 11: 735744.
  • 24
    Pugh RN, Lyon IM Murray, Dawson JL, Pietroni MC, Williams R. Tran-section of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646649.
  • 25
    Markowitz AJ, Chen YT, Muenzer J, Delbuono EA, Lucey MR. A man with type III glycogenosis associated with cirrhosis and portal hypertension. Gastroenterology 1993; 105: 18821885.
  • 26
    Ishihara M, Cameron O, Minoshima S, Drury I, Kuhl DE, Frey KA. PET determinations of benzodiazepine receptor occupancy by unlabelled drugs [Abstract]. J Nucl Med 1994; 35: 141P.
  • 27
    Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994; 35: 15281537.
  • 28
    Frey KA, Minoshima S, Koeppe RA, Kilbourne MR, Berger KL, Kuhl DE. Stereotaxic summation analysis of human cerebral benzodiazepine binding maps. J Cereb Blood Flow Metab 1996; 16: 409417.
  • 29
    Roy S, Layrargues G Pomier, Butterworth RF, Huet PM. Hepatic encephalopathy in cirrhotic and portacaval shunted dogs: lack of changes in brain GABA uptake, brain GABA levels, brain glutamic acid decarboxylase activity and brain postsynaptic GABA receptors. Hepatology 1988; 8: 845849.
  • 30
    Pappas SC, Levy GA, Gordon VP. Decreased brain GABA binding in a model of fulminant hepatic failure (FHF) evidence conflicting with the GABA hypothesis for hepatic encephalopathy [Abstract]. Hepatology 1986; 6: 1106A.
  • 31
    Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clin Pharmacokinet 1988; 14: 112.
  • 32
    Debruyne D, Abadie P, Barre L, Albessard F, Moulin M, Zarifian E, Baron JC. Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C]Ro 15-1788 (flumazenil) in baboon and human during positron emmission tomography studies. Eur J Drug Metab Pharmacokinet 1991; 16: 141152.
  • 33
    Swahn CG, Persson A, Pauli S. Metabolism of the benzodiazepine antagonist 11C-Ro 15-1788 after intravenous administration in man. Human Psychpharmacology 1989; 4: 297301.
  • 34
    Lockwood AH, Yap EW, Rhoades HM, Wong WH. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 1991; 11: 331336.